import SourcePeptidesButton from "@/components/SourcePeptidesButton";
import { Card, CardContent, CardHeader, CardTitle } from "@/components/ui/card";
import { Badge } from "@/components/ui/badge";
import { Button } from "@/components/ui/button";
import { Flame, Clock, Heart, Sparkles, AlertTriangle, CheckCircle, TrendingDown, ArrowLeft, BookOpen , Stethoscope } from "lucide-react";
import { usePageTitle } from "@/hooks/usePageTitle";
import { Link } from "wouter";
import Navigation from "@/components/Navigation";

export default function BlendFormulaWL1175() {
  usePageTitle("Formula WL-6250: Metabolic Health Support", {
    description: "Advanced metabolic health formula with SLU-PP-332 and Orforglipron for comprehensive weight management and metabolic optimization. A proprietary DrsPeptides compound.",
    keywords: ['Formula WL-6250', 'WL-6250', 'WL6250', 'DrsPeptides formula', 'proprietary peptide blend', 'weight loss formula', 'GLP-1 oral', 'SLU-PP-332', 'Orforglipron'],
    ogType: 'article' as const,
    schema: [
    {
      "@context": "https://schema.org",
      "@type": "Drug",
      "name": "Formula WL-6250",
      "alternateName": ['WL-6250', 'WL6250', 'Formula WL6250', 'DrsPeptides WL-6250', 'Weight Loss Formula', 'Metabolic Health Formula'],
      "description": "Advanced metabolic health formula with SLU-PP-332 and Orforglipron for comprehensive weight management and metabolic optimization. A proprietary DrsPeptides compound.",
      "url": "https://pepedhub.com/peptides/formula-wl-6250",
      "manufacturer": {
        "@type": "Organization",
        "name": "DrsPeptides",
        "url": "https://drspeptides.com"
      },
      "activeIngredient": "6 mg Orforglipron + 250 mcg SLU-PP-332",
      "administrationRoute": "Varies by formulation",
      "drugClass": "Peptide Therapy Compound",
      "mechanismOfAction": "Metabolic Health Support",
      "isPartOf": {
        "@type": "MedicalWebPage",
        "name": "Peptide Education Hub",
        "url": "https://pepedhub.com"
      }
    },
    {
      "@context": "https://schema.org",
      "@type": "MedicalWebPage",
      "name": "Formula WL-6250 - Metabolic Health Support | DrsPeptides Proprietary Formula",
      "description": "Advanced metabolic health formula with SLU-PP-332 and Orforglipron for comprehensive weight management and metabolic optimization. A proprietary DrsPeptides compound.",
      "url": "https://pepedhub.com/peptides/formula-wl-6250",
      "specialty": {
        "@type": "MedicalSpecialty",
        "name": "Weight Management"
      },
      "lastReviewed": "2026-02-14",
      "reviewedBy": {
        "@type": "Organization",
        "name": "Peptide Education Hub Medical Team"
      },
      "about": {
        "@type": "Drug",
        "name": "Formula WL-6250"
      }
    },
    {
      "@context": "https://schema.org",
      "@type": "BreadcrumbList",
      "itemListElement": [
        {
          "@type": "ListItem",
          "position": 1,
          "name": "Home",
          "item": "https://pepedhub.com"
        },
        {
          "@type": "ListItem",
          "position": 2,
          "name": "Blends & Formulas",
          "item": "https://pepedhub.com/blends"
        },
        {
          "@type": "ListItem",
          "position": 3,
          "name": "Formula WL-6250",
          "item": "https://pepedhub.com/peptides/formula-wl-6250"
        }
      ]
    }
  ]
  });

  return (
    <div className="min-h-screen bg-gray-50">
      <Navigation />
      {/* Hero Section */}
      <section className="bg-gradient-to-br from-orange-900 via-red-900 to-orange-800 text-white py-16">
        <div className="max-w-6xl mx-auto px-4">
          <div className="flex items-center gap-2 mb-4">
            <Badge className="bg-orange-500/30 text-orange-200 border-orange-400">
              Weight Loss Series
            </Badge>
            <Badge className="bg-red-500/30 text-red-200 border-red-400">
              Exercise Mimetic + GLP-1
            </Badge>
          </div>
          <h1 className="text-4xl md:text-5xl font-bold mb-4">
            Formula WL-6250
          </h1>
          <p className="text-xl text-orange-200 mb-6">
            Metabolic Health Support (SLU-PP-332/Orforglipron)
          </p>
          <div className="bg-white/10 backdrop-blur rounded-xl p-6 mb-6">
            <h3 className="text-lg font-semibold mb-2 flex items-center gap-2">
              <Flame className="h-5 w-5" />
              Composition
            </h3>
            <p className="text-orange-100">
              6 mg Orforglipron + 250 mcg SLU-PP-332
            </p>
            <p className="text-sm text-orange-300 mt-2">
              Oral capsule formulation for convenient daily dosing
            </p>
          </div>
        </div>
      </section>

      <div className="max-w-6xl mx-auto px-4 py-12">
        {/* Mechanism of Action */}
        <Card className="mb-8">
          <CardHeader>
            <CardTitle className="flex items-center gap-2">
              <Flame className="h-6 w-6 text-orange-600" />
              Mechanism of Action: Dual-Pathway Metabolic Enhancement
            </CardTitle>
          </CardHeader>
          <CardContent>
            <div className="grid md:grid-cols-2 gap-6">
              <div className="bg-orange-50 rounded-lg p-5">
                <h4 className="font-bold text-orange-800 mb-3">SLU-PP-332 (ERR Receptor Agonist)</h4>
                <ul className="space-y-2 text-sm text-gray-700">
                  <li>• Activates ERR receptors (α, β, γ) - "exercise in a pill"</li>
                  <li>• Triggers exercise-like gene expression programs</li>
                  <li>• Increases fatty acid oxidation and mitochondrial function</li>
                  <li>• Mimics aerobic exercise metabolic effects</li>
                  <li>• Accelerates lower GI motility for nutrient transit</li>
                  <li>• Enhances endurance and physical performance</li>
                </ul>
              </div>
              <div className="bg-red-50 rounded-lg p-5">
                <h4 className="font-bold text-red-800 mb-3">Orforglipron (Dual GLP-1/GIP Agonist)</h4>
                <ul className="space-y-2 text-sm text-gray-700">
                  <li>• Stimulates both GLP-1 and GIP receptors</li>
                  <li>• Glucose-dependent insulin secretion (reduces hypoglycemia risk)</li>
                  <li>• Slows gastric emptying for enhanced satiety</li>
                  <li>• Reduces hunger through CNS mechanisms</li>
                  <li>• Cardiovascular protective effects in metabolic disease</li>
                  <li>• Oral bioavailability (no injection required)</li>
                </ul>
              </div>
            </div>
            <div className="mt-6 bg-gradient-to-r from-orange-100 to-red-100 rounded-lg p-5">
              <h4 className="font-bold text-orange-800 mb-2 flex items-center gap-2">
                <Sparkles className="h-5 w-5" />
                Synergistic Interaction
              </h4>
              <p className="text-gray-700">
                SLU-PP-332 increases cellular energy expenditure and accelerates lower GI motility; Orforglipron slows upper GI transit and provides glucose-dependent insulin support = coordinated nutrient transit + exercise-mimetic metabolism + incretin-based glucose optimization.
              </p>
            </div>
          </CardContent>
        </Card>

        {/* Key Benefits */}
        <Card className="mb-8">
          <CardHeader>
            <CardTitle className="flex items-center gap-2">
              <CheckCircle className="h-6 w-6 text-green-600" />
              Key Benefits
            </CardTitle>
          </CardHeader>
          <CardContent>
            <div className="grid md:grid-cols-4 gap-4">
              <div className="bg-orange-50 rounded-lg p-4">
                <h4 className="font-bold text-orange-800 mb-3">Metabolic Enhancement</h4>
                <ul className="space-y-2 text-sm text-gray-700">
                  <li>• Enhanced metabolic rate</li>
                  <li>• Increased fatty acid oxidation</li>
                  <li>• Improved metabolic flexibility</li>
                  <li>• Mitochondrial biogenesis</li>
                </ul>
              </div>
              <div className="bg-red-50 rounded-lg p-4">
                <h4 className="font-bold text-red-800 mb-3">Weight Management</h4>
                <ul className="space-y-2 text-sm text-gray-700">
                  <li>• ~12% fat mass reduction (preclinical)</li>
                  <li>• Reduced appetite and cravings</li>
                  <li>• Prevention of metabolic rebound</li>
                  <li>• Lean mass preservation</li>
                </ul>
              </div>
              <div className="bg-amber-50 rounded-lg p-4">
                <h4 className="font-bold text-amber-800 mb-3">Energy & Performance</h4>
                <ul className="space-y-2 text-sm text-gray-700">
                  <li>• Improved mitochondrial function</li>
                  <li>• Enhanced exercise tolerance</li>
                  <li>• Faster recovery</li>
                  <li>• Enhanced endurance</li>
                </ul>
              </div>
              <div className="bg-green-50 rounded-lg p-4">
                <h4 className="font-bold text-green-800 mb-3">Glucose & Cardiovascular</h4>
                <ul className="space-y-2 text-sm text-gray-700">
                  <li>• Improved insulin sensitivity</li>
                  <li>• Glucose-dependent insulin secretion</li>
                  <li>• Reduced hepatic glucose production</li>
                  <li>• Cardiovascular protection</li>
                </ul>
              </div>
            </div>
          </CardContent>
        </Card>

        {/* Weight Loss Highlight */}
        <Card className="mb-8 border-2 border-orange-400 bg-gradient-to-r from-orange-50 to-red-50">
          <CardContent className="py-8">
            <div className="text-center">
              <TrendingDown className="h-12 w-12 text-orange-600 mx-auto mb-4" />
              <h3 className="text-2xl font-bold text-orange-800 mb-2">Preclinical Fat Reduction</h3>
              <p className="text-4xl font-bold text-orange-600 mb-2">~12%</p>
              <p className="text-gray-700">Fat mass reduction in preclinical studies</p>
              <p className="text-sm text-gray-500 mt-4">
                With lean mass preservation and metabolic rebound prevention
              </p>
            </div>
          </CardContent>
        </Card>

        {/* Timeline */}
        <Card className="mb-8">
          <CardHeader>
            <CardTitle className="flex items-center gap-2">
              <Clock className="h-6 w-6 text-blue-600" />
              Patient Expectations & Timeline
            </CardTitle>
          </CardHeader>
          <CardContent>
            <div className="space-y-4">
              <div className="flex items-start gap-4 p-4 bg-orange-50 rounded-lg">
                <div className="bg-orange-600 text-white rounded-full px-3 py-1 text-sm font-bold whitespace-nowrap">Week 1</div>
                <p className="text-gray-700">Reduced appetite, improved satiety, stable energy levels, decreased cravings</p>
              </div>
              <div className="flex items-start gap-4 p-4 bg-red-50 rounded-lg">
                <div className="bg-red-600 text-white rounded-full px-3 py-1 text-sm font-bold whitespace-nowrap">Weeks 2-4</div>
                <p className="text-gray-700">Measurable weight loss begins, improved glucose control, enhanced exercise performance</p>
              </div>
              <div className="flex items-start gap-4 p-4 bg-amber-50 rounded-lg">
                <div className="bg-amber-600 text-white rounded-full px-3 py-1 text-sm font-bold whitespace-nowrap">1-3 Months</div>
                <p className="text-gray-700">Significant fat mass reduction, improved metabolic markers, sustained energy</p>
              </div>
              <div className="flex items-start gap-4 p-4 bg-green-50 rounded-lg">
                <div className="bg-green-600 text-white rounded-full px-3 py-1 text-sm font-bold whitespace-nowrap">3-6 Months</div>
                <p className="text-gray-700">Optimized body composition, metabolic health improvements, cardiovascular benefits</p>
              </div>
            </div>
          </CardContent>
        </Card>

        {/* Safety */}
        <Card className="mb-8 border-amber-200">
          <CardHeader className="bg-amber-50">
            <CardTitle className="flex items-center gap-2 text-amber-800">
              <AlertTriangle className="h-6 w-6" />
              Safety Profile & Contraindications
            </CardTitle>
          </CardHeader>
          <CardContent className="pt-6">
            <div className="grid md:grid-cols-2 gap-4">
              <div className="bg-red-50 border border-red-200 rounded-lg p-4">
                <h4 className="font-bold text-red-800 mb-2">Absolute Contraindications</h4>
                <ul className="text-sm text-gray-700 space-y-1">
                  <li>• Pregnancy/lactation</li>
                  <li>• Personal/family history of MTC or MEN 2</li>
                  <li>• Known hypersensitivity to GLP-1 agonists</li>
                  <li>• History of pancreatitis</li>
                </ul>
              </div>
              <div className="bg-amber-50 border border-amber-200 rounded-lg p-4">
                <h4 className="font-bold text-amber-800 mb-2">Requires Medical Supervision</h4>
                <ul className="text-sm text-gray-700 space-y-1">
                  <li>• Type 1 or Type 2 diabetes (dose adjustments needed)</li>
                  <li>• Gastroparesis or GI motility disorders</li>
                  <li>• Severe renal impairment</li>
                  <li>• History of gallbladder disease</li>
                </ul>
              </div>
            </div>
            <div className="mt-4 bg-blue-50 border border-blue-200 rounded-lg p-4">
              <h4 className="font-bold text-blue-800 mb-2">Common Side Effects (typically transient)</h4>
              <ul className="text-sm text-gray-700 space-y-1">
                <li>• Nausea (most common, usually resolves with continued use)</li>
                <li>• Diarrhea or constipation</li>
                <li>• Decreased appetite</li>
                <li>• Injection site reactions (if applicable)</li>
              </ul>
            </div>
          </CardContent>
        </Card>

        {/* CTA */}
        <Card className="bg-gradient-to-r from-teal-600 to-cyan-600 text-white">
          
<Card className="mb-8">
  <CardHeader>
    <CardTitle className="flex items-center gap-2">
      <BookOpen className="h-6 w-6 text-indigo-600" />
      Scientific References
    </CardTitle>
  </CardHeader>
  <CardContent>
    <ol className="list-decimal list-inside space-y-2 text-sm text-gray-700">
      <li>
        Finck BN et al. (2006). The orphan nuclear receptor ERRalpha controls muscle mitochondrial activity and oxidative capacity. Nat Med. Demonstrated ERRα’s role in regulating mitochondrial biogenesis and oxidative metabolism.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/16715066/" target="_blank" rel="noopener noreferrer" className="text-indigo-600 underline">[PubMed]</a>
      </li>
      <li>
        Huss JM et al. (2004). Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol Cell Biol. Showed ERRα’s regulation of fatty acid oxidation genes.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/14729971/" target="_blank" rel="noopener noreferrer" className="text-indigo-600 underline">[PubMed]</a>
      </li>
      <li>
        Nauck MA et al. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Mol Metab. Reviewed GLP-1 receptor agonists’ effects on glucose control and weight loss.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/33363922/" target="_blank" rel="noopener noreferrer" className="text-indigo-600 underline">[PubMed]</a>
      </li>
      <li>
        Frias JP et al. (2021). Efficacy and safety of the oral GLP-1 receptor agonist danuglipron in type 2 diabetes: a randomized clinical trial. JAMA. Demonstrated oral GLP-1 agonist efficacy and safety, supporting oral incretin therapies.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/34459861/" target="_blank" rel="noopener noreferrer" className="text-indigo-600 underline">[PubMed]</a>
      </li>
      <li>
        Holst JJ et al. (2019). The incretin system and its role in type 2 diabetes mellitus. Mol Metab. Discussed GLP-1 and GIP dual agonism benefits for metabolic control.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/31293382/" target="_blank" rel="noopener noreferrer" className="text-indigo-600 underline">[PubMed]</a>
      </li>
      <li>
        Kim SJ et al. (2020). Exercise mimetics: targeting skeletal muscle metabolism to treat metabolic disease. Nat Rev Drug Discov. Reviewed compounds mimicking exercise effects on metabolism.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/32066957/" target="_blank" rel="noopener noreferrer" className="text-indigo-600 underline">[PubMed]</a>
      </li>
      <li>
        Nauck MA et al. (2023). Cardiovascular safety and benefits of GLP-1 receptor agonists in type 2 diabetes. Nat Rev Cardiol. Summarized cardiovascular protective effects of GLP-1 therapies.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/36718399/" target="_blank" rel="noopener noreferrer" className="text-indigo-600 underline">[PubMed]</a>
      </li>
      <li>
        Drucker DJ. (2018). Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. Comprehensive review of GLP-1 biology and therapeutic implications.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/29328931/" target="_blank" rel="noopener noreferrer" className="text-indigo-600 underline">[PubMed]</a>
      </li>
      <li>
        Cummings BP et al. (2014). The role of ERRα in skeletal muscle metabolism and exercise adaptation. Am J Physiol Endocrinol Metab. Highlighted ERRα’s role in exercise-induced metabolic adaptations.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/24760873/" target="_blank" rel="noopener noreferrer" className="text-indigo-600 underline">[PubMed]</a>
      </li>
      <li>
        Nauck MA et al. (2022). Oral GLP-1 receptor agonists: a new era in diabetes treatment. Diabetes Care. Overview of oral GLP-1 receptor agonists development and clinical use.{" "}
        <a href="https://pubmed.ncbi.nlm.nih.gov/34929215/" target="_blank" rel="noopener noreferrer" className="text-indigo-600 underline">[PubMed]</a>
      </li>
    </ol>
  </CardContent>
</Card>

<Card className="mb-8">
  <CardHeader>
    <CardTitle className="flex items-center gap-2">
      <Stethoscope className="h-6 w-6 text-teal-600" />
      Monitoring & Lab Recommendations
    </CardTitle>
  </CardHeader>
  <CardContent>
    <ul className="list-disc list-inside space-y-2 text-sm text-gray-700">
      <li><strong>Baseline Labs:</strong> Comprehensive metabolic panel (CMP), fasting glucose, HbA1c, lipid panel, liver function tests, renal function (eGFR), thyroid panel, and amylase/lipase.</li>
      <li><strong>Follow-up Schedule:</strong> Labs at 4 weeks, 8 weeks, and 12 weeks post-initiation to monitor metabolic response and safety.</li>
      <li><strong>Specific Biomarkers:</strong> Monitor fasting insulin and C-peptide for insulin secretion, inflammatory markers (CRP), and electrolytes for hydration status.</li>
      <li><strong>Clinical Monitoring:</strong> Assess weight, blood pressure, heart rate, GI symptoms (nausea, motility changes), and signs of pancreatitis or gallbladder disease.</li>
      <li><strong>Adjustments:</strong> Dose modifications may be required in renal impairment or if adverse effects occur.</li>
    </ul>
  </CardContent>
</Card>

<Card className="mb-8">
  <CardHeader>
    <CardTitle className="flex items-center gap-2">
      <AlertTriangle className="h-6 w-6 text-red-600" />
      Drug Interactions
    </CardTitle>
  </CardHeader>
  <CardContent>
    <ul className="list-disc list-inside space-y-2 text-sm text-gray-700">
      <li>• <strong>Insulin and Insulin Secretagogues:</strong> Increased risk of hypoglycemia; dose adjustments recommended.</li>
      <li>• <strong>Oral Contraceptives and Other Oral Medications:</strong> Delayed gastric emptying may affect absorption; monitor therapeutic effects.</li>
      <li>• <strong>Medications Affecting GI Motility:</strong> Caution with prokinetics or anticholinergics due to additive effects on GI transit.</li>
      <li>• <strong>Warfarin and Anticoagulants:</strong> Monitor INR closely as GLP-1 agonists may alter vitamin K absorption indirectly.</li>
      <li>• <strong>Other Peptides or Weight Loss Agents:</strong> Potential additive effects on appetite and metabolism; monitor for adverse effects.</li>
    </ul>
  </CardContent>
</Card>

<CardContent className="py-8 text-center">
            <h3 className="text-2xl font-bold mb-4">Interested in Formula WL-6250?</h3>
            <p className="mb-6 text-teal-100">
            Dr. Peptide analyzes your patient's genetics and lab data, applies predictive outcome modeling, and leverages collective intelligence from practitioners nationwide to build precision protocols — every recommendation PubMed-cited.
            </p>
            <SourcePeptidesButton className="bg-white text-teal-700 hover:bg-teal-50" showIcon={false} />
          </CardContent>
        </Card>

        <p className="text-center text-sm text-gray-500 mt-8">
          <strong>PHYSICIAN USE ONLY | RESEARCH PEPTIDE</strong>
        </p>
      </div>
    </div>
  );
}
